Skip to main content

PINK1 Antibody (8E10.1D6) - BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-36488

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP2-36488
NBP2-36488SS

Key Product Details

Validated by

Knockout/Knockdown, Biological Validation

Species Reactivity

Validated:

Human, Mouse, Rat

Cited:

Human, Mouse, Rat

Predicted:

Primate (100%). Backed by our 100% Guarantee.

Applications

Validated:

Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Knockdown Validated, SDS-Page, Western Blot

Cited:

Immunocytochemistry/ Immunofluorescence, Immunohistochemistry-Paraffin, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2b Kappa Clone # 8E10.1D6

Format

BSA Free

Concentration

1.0 mg/ml

Product Specifications

Immunogen

PINK1 antibody was developed using a synthetic peptide made to the human PINK1 protein sequence (between residues 100-250).

Reactivity Notes

Mouse reactivity reported in scientific literature (PMID: 29486776). Use in Rat reported in scientific literature (PMID:32365512).

Localization

Mitochondrion outer membrane, Cytoplasm

Specificity

Human PINK1 protein sequence (between residues 100-250), only reactive to isoform 1.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2b Kappa

Theoretical MW

62.7 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Scientific Data Images for PINK1 Antibody (8E10.1D6) - BSA Free

Knockdown Validated: PINK1 Antibody (8E10.1D6) - BSA Free [NBP2-36488]

Knockdown Validated: PINK1 Antibody (8E10.1D6) - BSA Free [NBP2-36488]

Knockdown Validated: PINK1 Antibody (8E10.1D6) [NBP2-36488] - PINK1 is responsible for CMR-induced cytoplasmic vacuolation.The effect of siRNA-mediated knockdown of PINK1 on CMR-induced changes in the expression of Alix in MDA-MB-231 cells as analyzed by Western blot (left panel) All cells were treated with 6 uM CMR for 48 h. Image collected and cropped by Citeab from the following publication (Chalcomoracin is a potent anticancer agent acting through triggering Oxidative stress via a mitophagy- and paraptosis-dependent mechanism. Sci Rep (2018) licensed under a CC-BY license.
Immunohistochemistry-Paraffin: PINK1 Antibody (8E10.1D6) - BSA Free [NBP2-36488]

Immunohistochemistry-Paraffin: PINK1 Antibody (8E10.1D6) - BSA Free [NBP2-36488]

Immunohistochemistry-Paraffin: PINK1 Antibody (8E10.1D6) [NBP2-36488] - Analysis of FFPE tissue section of human hepatocellular carcinoma using PINK1 antibody (clone 8E10.1D6) at 5 ug/ml concentration. The cancer cells developed an expected punctate to granular cytoplasmic staining with no signal in the tumor stroma.
Immunocytochemistry/ Immunofluorescence: PINK1 Antibody (8E10.1D6) - BSA Free [NBP2-36488]

Immunocytochemistry/ Immunofluorescence: PINK1 Antibody (8E10.1D6) - BSA Free [NBP2-36488]

Immunocytochemistry/Immunofluorescence: PINK1 Antibody (8E10.1D6) [NBP2-36488] - HeLa cells were treated with valinomycin (1 uM, 24h) prior to being fixed in 10% buffered formalin for 10 min and permeabilized in 0.1% Triton X-100 in PBS for 10 min. Cells were incubated with NBP2-36488 at 50 ug/ml for 1hr at room temperature, washed 3x in PBS and incubated with Alexa-DyLight-488 anti-mouse secondary antibody. PINK1 (Green) was detected at the mitochondria. Tubulin (Red) was detected using an anti-tubulin antibody with an anti-rabbit DyLight 550 secondary antibody. DNA (Blue) was counterstained with DAPI. Note: mitochondria staining might not be easily observed without treatment with valinomycin or CCCP. Image objective 40x.

Applications for PINK1 Antibody (8E10.1D6) - BSA Free

Application
Recommended Usage

Immunocytochemistry/ Immunofluorescence

20-50 ug/ml

Immunohistochemistry

5 ug/ml

Immunohistochemistry-Paraffin

5 ug/ml

SDS-Page

reported in scientific literature (PMID 27553674)

Western Blot

2-4 ug/ml
Application Notes
Unprocessed PINK1 is 63 kDa which undergoes proteolytic processing to generate 55 kDa and 42 kDa cleaved forms, and bands at the mentioned positions may be expected in Western blot application.

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

PBS

Format

BSA Free

Preservative

0.05% Sodium Azide

Concentration

1.0 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: PINK1

Phosphatase and Tensin Homolog (PTEN) is a tumor suppressor which acts as an antagonist to phosphatidylinositol 3-kinase (PI3K) signaling. PTEN exerts enzymatic activity as a phosphatidylinositol-3,4,5-trisphosphate (PIP3) phosphatase, opposing PI3K activity by reducing availability of PIP3 to proliferating cells. Loss of PTEN function leads to elevated PIP3 and increased activation of PI3K/AKT signaling in many types of cancer.

PINK1 (PTEN induced putative kinase 1) protein contains a N-terminal mitochondrial targeting sequence, putative transmembrane helix, linker region, serine (Ser65)/threonine (Thr257) kinase domain and C-terminal segment. PINK1 is translated in the cytosol, then translocated to the outer mitochondrial membrane where it is rapidly cleaved and degraded as a part of normal mitochondrial function. In damaged (depolarized) mitochondria, PINK1 becomes stabilized and accumulates, resulting in the subsequent phosphorylation of numerous proteins on the mitochondrial surface.

When PINK1 is imported into the cell, mitochondrial processing peptidase, presenilin-associated rhomboid-like protease and AFG3L2 cleave PINK1 and tag it for the ubiquitin-proteasome pathway, keeping low PINK1 protein expression at basal conditions (1,2). Accumulation of PINK1 in mitochondria indicate damage. PINK1 maintains mitochondrial function/integrity, provides protection against mitochondrial dysfunction during cellular stress, and is involved in the clearance of damaged mitochondria via selective autophagy (mitophagy) (3). PINK1 has a theoretical molecular weight of 63 kDa and undergoes proteolytic processing to generate at least two cleaved forms (55 kDa and 42 kDa).

Ultimately PARK2 (E3 Ubiquitin Ligase Parkin) is recruited to the damaged mitochondria where it is activated by 1) PINK-mediated phosphorylation of PARK2 at serine 65, and 2) PARK2 interaction with phosphorylated ubiquitin (also phosphorylated by PINK1 on serine 65) (4,5). There is a strong interplay between Parkin and PINK1, where loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by Parkin (2,4,5). Mutations in either Parkin or PINK1 alter mitochondrial turnover, resulting in the accumulation of defective mitochondria and, ultimately, neurodegeneration in Parkinson's disease. Mutations in the PINK1 gene located within the PARK6 locus on chromosome 1p35-p36 have been identified in patients with early-onset Parkinson's disease (6).

References

1.Rasool, S., Soya, N., Truong, L., Croteau, N., Lukacs, G. L., & Trempe, J. F. (2018). PINK1 autophosphorylation is required for ubiquitin recognition. EMBO Rep, 19(4). doi:10.15252/embr.201744981

2.Shiba-Fukushima, K., Arano, T., Matsumoto, G., Inoshita, T., Yoshida, S., Ishihama, Y., . . . Imai, Y. (2014). Phosphorylation of mitochondrial polyubiquitin by PINK1 promotes Parkin mitochondrial tethering. PLoS Genet, 10(12), e1004861. doi:10.1371/journal.pgen.1004861

3.Vives-Bauza, C., Zhou, C., Huang, Y., Cui, M., de Vries, R. L., Kim, J., . . . Przedborski, S. (2010). PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A, 107(1), 378-383. doi:10.1073/pnas.0911187107

4.McWilliams, T. G., Barini, E., Pohjolan-Pirhonen, R., Brooks, S. P., Singh, F., Burel, S., . . . Muqit, M. M. K. (2018). Phosphorylation of Parkin at serine 65 is essential for its activation in vivo. Open Biol, 8(11). doi:10.1098/rsob.180108

5.Exner, N., Treske, B., Paquet, D., Holmstrom, K., Schiesling, C., Gispert, S., . . . Haass, C. (2007). Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci, 27(45), 12413-12418. doi:10.1523/jneurosci.0719-07.2007

6.Valente, E. M., Bentivoglio, A. R., Dixon, P. H., Ferraris, A., Ialongo, T., Frontali, M., . . . Wood, N. W. (2001). Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet, 68(4), 895-900. doi:10.1086/319522

Long Name

PTEN-induced Putative Kinase 1

Alternate Names

BRPK, PARK6, PINK1 monoclonal

Entrez Gene IDs

65018 (Human)

Gene Symbol

PINK1

OMIM

605909 (Human)

UniProt

Additional PINK1 Products

Product Documents for PINK1 Antibody (8E10.1D6) - BSA Free

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for PINK1 Antibody (8E10.1D6) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...